Kralovicova K, Spanik S, Oravcova E, Mrazova M, Morova E, Gulikova V, Kukuckova E, Koren P, Pichna P, Nogova J, Kunova A, Trupl J, Krcmery V
Department of Medicine, Post-graduate Medical School, University of Trnava, Slovakia.
Scand J Infect Dis. 1997;29(3):301-4. doi: 10.3109/00365549709019047.
26 patients with fungemia and cancer treated with chemotherapy (group A) were compared to 25 patients with fungemia and cancer treated with surgery (group B), to assess differences in etiology, risk factors and outcome. Candida albicans was responsible for 42% of fungemias in group A, and for 92% of fungemias in group B (p < 0.005). Breakthrough fungemia occurring during antifungal prophylaxis appeared in 46.6% of group A vs 12% of group B (p < 0.02). There was significant difference in outcome between the groups: 20% of patients after surgery vs 7.7% of those after chemotherapy died from fungemia (p < 0.04). Most common risk factors recorded in both groups were catheter insertion and previous therapy with broad spectrum antibiotics.
将26例接受化疗的真菌血症合并癌症患者（A组）与25例接受手术治疗的真菌血症合并癌症患者（B组）进行比较，以评估病因、危险因素及预后的差异。白色念珠菌导致A组42%的真菌血症，B组92%的真菌血症（p<0.005）。抗真菌预防期间出现的突破性真菌血症在A组占46.6%，B组占12%（p<0.02）。两组预后存在显著差异：手术后患者中有20%死于真菌血症，化疗后患者中则为7.7%（p<0.04）。两组记录的最常见危险因素均为导管插入和先前使用广谱抗生素治疗。
